Kan, Hong

Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis

Hankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., Griffin, R., Stefanski, A., & Garvey, W. T. (2024) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 97

Clinical outcomes associated with anti‐obesity medications in real‐world practice: A systematic literature review

Ahmad, N. N., Robinson, S., Kennedy‐Martin, T., Poon, J. L., & Kan, H. (2021) · Obesity Reviews

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 69

Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT ‐1 trial

Hankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., Stefanski, A., & Garvey, W. T. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 44

Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison

le Roux, C. W., Hankosky, E. R., Wang, D., Malik, R., Yu, M., Hickey, A., Kan, H., Bunck, M. C., Stefanski, A., Garcia‐Perez, L., et al. (2023) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 36

Weight management treatment modalities in patients with overweight or obesity: A retrospective cohort study of administrative claims data

Kan, H., Swindle, J. P., Bae, J., Dunn, J. P., Buysman, E. K., Gronroos, N. N., Bengtson, L., Chinthammit, C., Ford, J., & Ahmad, N. (2023) · Obesity Pillars

Bariatric Surgery and OutcomesPharmacology and Obesity Treatment

Cited by 10